Page 40 - Medication Guide News Today

-- Oral presentation on KRYSTEXXA (pegloticase injection) plus methotrexate to be held June 2, 2022 at 11:35 a.m. CEST-- -- Additional data presentations provide new insights on psychosocial and

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou...

/PRNewswire/ -- Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Taye Diggs, esteemed actor, author and father, as a patient ambassador...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant

Opinion granted based on positive results from the Phase 3 KEYNOTE-716 trial If approved, KEYTRUDA would be the first anti-PD-1 immunotherapy treatment option for patients 12 years and older in

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Following the launch of QUVIVIQ™ (daridorexant) CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced today that the first wave of...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

Key data includes ASCO oral presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN